Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation...

Area of Science:

• Cellular Biology
• Molecular Oncology
• Radiation Oncology

Background:

• Ionizing radiation (IR) is a cornerstone of cancer treatment.
• Understanding the molecular mechanisms of IR-induced cellular responses is crucial for optimizing therapy.
• ERK signaling pathway plays a significant role in cell proliferation and survival.

Purpose of the Study:

• To elucidate the specific signaling pathways involved in IR-induced ERK activation in MDA-MB-468 cells.
• To determine the roles of epidermal growth factor receptor (EGFR) and Src kinase in this process.
• To differentiate IR-induced signaling from canonical EGFR ligand-dependent pathways.

Main Methods:

• Cell culture of MDA-MB-468 cells.
• Exposure to ionizing radiation (IR).
• Western blot analysis to detect protein phosphorylation (ERK, EGFR, Src, SHP-2, PTPalpha).
• Pharmacological inhibition using specific inhibitors (AG1478 for EGFR, PP2 for Src, Wortmannin for PI3K).

Main Results:

• IR induced biphasic ERK1/2 phosphorylation.
• EGFR and Src inhibitors, but not PI3K inhibitor, blocked IR-induced ERK activation.
• IR induced EGFR tyrosine phosphorylation and Src activation (phosphorylation at Tyr416).
• IR activated SHP-2 in a Src-dependent manner.
• IR-induced EGFR phosphorylation was not at canonical autophosphorylation sites or Src-dependent Tyr845.

Conclusions:

• IR-induced ERK1/2 activation in MDA-MB-468 cells is mediated by EGFR and Src kinase.
• This activation occurs through a Src-dependent pathway distinct from EGFR ligand stimulation.
• SHP-2 is activated downstream of Src in this IR-response pathway.
• Targeting this IR-specific EGFR-Src-SHP-2-ERK axis may offer novel therapeutic strategies in radiation oncology.